Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France

Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
doi: https://doi.org/10.1101/2023.03.17.23287411

Article Information

doi 
https://doi.org/10.1101/2023.03.17.23287411
History 
  • March 18, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Vincent Auvigne#,1,*,
  2. Cynthia Tamandjou#,1,
  3. Justine Schaeffer1,
  4. Sophie Vaux1 and
  5. Isabelle Parent du Chatelet1
  1. 1Direction des maladies infectieuses - Unité infections respiratoires et vaccination, Santé publique France, Public Health France. F-94415 Saint-Maurice, France
  1. ↵*Corresponding author: Vincent Auvigne vincent.auvigne{at}santepubliquefrance.fr +33 (0)1 55 12 51 89

  1. ↵# these authors contributed equally to this work

Back to top
Posted March 18, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Protection against symptomatic SARS-CoV-2 BA.5 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original (ancestral) monovalent vaccines – a matched cohort study in France
Vincent Auvigne, Cynthia Tamandjou, Justine Schaeffer, Sophie Vaux, Isabelle Parent du Chatelet
medRxiv 2023.03.17.23287411; doi: https://doi.org/10.1101/2023.03.17.23287411
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area